白蛋白紫杉醇治疗复发性广泛期小细胞肺癌的疗效观察

doi:10.13438/j.cnki.jdzk.2020.02.016

吉首大学学报（自然科学版）

白蛋白紫杉醇治疗复发性广泛期小细胞肺癌的疗效观察

徐朝久，赵景胜，陈超英，龙剑，梁静

（湘西自治州人民医院肿瘤科，湖南吉首 416000）

出版日期:2020-03-25 发布日期:2020-09-08
作者简介:徐朝久（1967—）, 男, 湖南泸溪人, 硕士, 湘西自治州人民医院肿瘤科主任医师, 主要从事恶性肿瘤化疗及姑息治疗研究.

Efficacy and Safety of Nab-Paclitaxel for Relapsed Extensive-Stage Small-Cell Lung Cancer

XU Chaojiu, ZHAO Jingsheng, CHEN Chaoying, LONG Jian, LIANG Jing

(Department of Oncology, People's Hospital of Xiangxi Autonomous Prefecture, Jishou 416000, Hunan China)

Online:2020-03-25 Published:2020-09-08

摘要/Abstract

摘要：

目的探讨白蛋白紫杉醇治疗复发广泛期小细胞肺癌的临床疗效和不良反应.方法 2017 年6月至2019 年6 月期间患者24例，行白蛋白紫杉醇130 mg/m （d1，8，15）单药静脉化疗，每4周为1个疗程，每2个疗程评价疗效.结果 24例患者中，部分缓解（PR）8例（33.3%），疾病稳定（SD）7例（29.2%），疾病进展（PD）9 例（37.5%）；客观缓解率（ORR）33.3%，疾病控制率（DCR）62.5%；中位无进展生存时间（mPFS）3.6个月，中位总生存时间（mOS）8.3个月.主要不良反应为，中性粒细胞减少(37.5% )，脱发(29.2% )，外周神经毒性(16.7% ).结论白蛋白紫杉醇治疗复发难治广泛期小细胞肺癌有一定疗效，不良反应可以耐受，值得进一步开展大样本研究.

关键词： 白蛋白紫杉醇, 广泛期小细胞肺癌, 化疗

Abstract:

The clinical efficacy and adverse effects of nab-paclitaxel in patients with relapsed extensive-stage small-cell lung cancer have been researched. Clinical data of 24 relapsed extensive-stage small-cell lung cancer patients who received nab-paclitaxel as single agent between June 2017 and June 2019 were collected, and the curative and adverse effects of the compound were evaluated. All patients were treated with 130 mg/m nab-paclitaxel on days 1, 8, and 15. The cycle was repeated every 4 weeks. Clinical efficacy was evaluated every two cycles. Results showed that among 24 patients, including 18 males and 6 females, the median age being 65 years （range 45～77 years）, 8 patients (33.3%) achieved partial response, 7 patients (29.2%) had a stable disease, and 9 patients (37.5%) had progressive disease. The objective response rate was 33.3%, and the disease control rate was 62.5%. The median progression-free survival was 3.6 months and median overall survival was 8.3 months. The major adverse reactions included neutropenia (37.5% ), alopecia (29.2% ), and sensory neuropathy (16.7% ). It can be concluded that nab-paclitaxel has curative effects, and its adverse effects are tolerable. Further research with a larger sample size is warranted to confirm these results.

Key words: nab-paclitaxel, extensive-stage small-cell lung cancer, chemotherapy

徐朝久，赵景胜，陈超英，龙剑，梁静. 白蛋白紫杉醇治疗复发性广泛期小细胞肺癌的疗效观察[J]. 吉首大学学报（自然科学版）, DOI: 10.13438/j.cnki.jdzk.2020.02.016.

XU Chaojiu, ZHAO Jingsheng, CHEN Chaoying, LONG Jian, LIANG Jing. Efficacy and Safety of Nab-Paclitaxel for Relapsed Extensive-Stage Small-Cell Lung Cancer[J]. Journal of Jishou University（Natural Sciences Edition), DOI: 10.13438/j.cnki.jdzk.2020.02.016.

参考文献

[1] VISHNU P, ROY V. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer[J]. Breast Cancer (Auckl), 2011(5): 53-65.
[2] GRADISHAR W J, TJULANDIN S, DAVIDSON N, et al. Phase Ⅲ Trial of Nanoparticle Albumin-Bound Paclitaxel Compared with Polyethylated Castor Oil-Based Paclitaxel in Women with Breast Cancer[J]. J Clin Oncol, 2005, 23(31): 7794-7803.
[3] MARIA A B, CLORINDA S, ANTONIO R. Treatment of Advanced Non-Small Cell Lung Cancer[J]. J Thorac Dis, 2011, 3(2): 122-133.
[4] EISENHAUER E A, THERASSE P, BOGAERTS, et al. New Response Evaluation Criteria in Solid Tumours: Revised Recist Guideline (Version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
[5] 何敬波,雷琳,袁佳,等.二线不同化疗方案治疗小细胞肺癌的疗效和安全性比较[J].实用癌症杂志,2017,32(1):61-63.
[6] STEFFENS C C, ELENDER C, HUTZSCHENREUTER U, et al. Treatment and Outcome of 432 Patients with Extensive-Stage Small Cell Lung Cancer in First, Second and Third Line-Results from the Prospective German TLK Cohort Study[J]. Lung Cancer, 2019, 130: 216-225.
[7] VON PAWEL J, JOTTE R, SPIGEL D R, et al. Randomized Phase Ⅲ Trial of Amrubicin Versus Topotecanas Second-Line Treatment for Patients with Small-Cell Lung Cancer[J]. J Clin Oncol, 2014, 32: 4012-4019.
[8] JOTTE R, CONKLING P, REYNOLDS C, et al. Randomized Phase Ⅱ Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients with Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy[J]. J Clin Oncol, 2011, 29: 287-293.
[9] 徐朝久,张灿珍，丁纯志,等.拓扑替康联合顺铂治疗小细胞肺癌的临床研究[J].肿瘤防治研究,2004,31(12):776-778.
[10] MARIA A B, CLORINDA S, ANTONIO R. Treatment of Advanced Non-Small Cell Lung Cancer[J]. J Thorac Dis, 2011, 3(2): 122-133.
[11] RIZVI N A, RIELY G J, AZZOLI C G, et al. Phase Ⅰ/Ⅱ Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel as Initial Chemotherapy in Patients with Stage Ⅳ Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2008, 26(4): 639-643.
[12] YOSHIDA H, KIM Y H, OZASA H, et al. Albumin-Bound Paclitaxel for the Treatment of Refractory or Relapsed Small-Cell Lung Cancer[J]. Mol Clin Oncol, 2016, 5(1): 213-215.
[13] NAITO Y, TAMIYA A, TAMIYA M, et al. Efficacy of Nanoparticle Albumin-Bound Paclitaxel Regimens for Relapsed Small-Cell Lung Cancer: A Retrospective Analysis[J]. Medicine, 2017, 96(35): e7884.
[14] MU J W, GAO S G, XUE Q, et al. A Matched Comparison Study of Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early-stage Nonsmall Cell Lung Cancer[J]. Chinese Medical Journal, 2015, 128(20): 2731-2735.

白蛋白紫杉醇治疗复发性广泛期小细胞肺癌的疗效观察

Efficacy and Safety of Nab-Paclitaxel for Relapsed Extensive-Stage Small-Cell Lung Cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价